BridgeBio Pharma (BBIO) Net Cash Flow (2018 - 2026)
BridgeBio Pharma (BBIO) posted Net Cash Flow of $309.9 million for Q1 2026, up 524.75% sequentially from -$73.0 million in Q4 2025, and up 320.55% YoY from $73.7 million in Q1 2025.
BridgeBio Pharma (BBIO) Net Cash Flow (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Net Cash Flow for 9 years, with the latest figure at $309.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 320.55% year-over-year to $309.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $339.3 million (up 420.0% YoY) and the FY2025 annual result came in at -$111.1 million, down 138.51% from the prior year.
- Net Cash Flow grew to $309.9 million in Q1 2026 per BBIO's latest filing, from -$73.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $309.9 million in Q1 2026 and troughed at -$141.6 million in Q3 2024.
- A 5-year average of $28.6 million and a median of $13.1 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow soared 1418.35% in 2023, then plunged 269.76% in 2025.
- Over 5 years, Net Cash Flow stood at -$68.9 million in 2022, then tumbled by 87.82% to -$129.4 million in 2023, then soared by 312.79% to $275.4 million in 2024, then slumped by 126.49% to -$73.0 million in 2025, then surged by 524.75% to $309.9 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $309.9 million, -$73.0 million, and -$106.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | -201.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -201.98 Mn |
| Jun 30, 2026 | -201.98 Mn |
| Mar 31, 2026 | 309.88 Mn |
| Mar 31, 2026 | 309.88 Mn |
| Dec 31, 2025 | -72.96 Mn |
| Dec 31, 2025 | -72.96 Mn |
| Sep 30, 2025 | -106.00 Mn |
| Sep 30, 2025 | -106.00 Mn |
| Jun 30, 2025 | 208.36 Mn |
| Jun 30, 2025 | 208.36 Mn |
| Mar 31, 2025 | -140.50 Mn |
| Mar 31, 2025 | -140.50 Mn |
| Dec 31, 2024 | 275.37 Mn |
| Dec 31, 2024 | 275.37 Mn |
| Sep 30, 2024 | -141.63 Mn |
| Sep 30, 2024 | -141.63 Mn |
| Jun 30, 2024 | 72.01 Mn |
| Jun 30, 2024 | 72.01 Mn |
| Mar 31, 2024 | 82.76 Mn |
| Mar 31, 2024 | 82.76 Mn |